Adding ipilimumab to standard melanoma therapy based on ctDNA
Treatments studied
Part of Cancer, Skin clinical trials.
This trial tests whether adding a second immunotherapy drug (ipilimumab) to the standard first-line combo of nivolumab and relatlimab improves outcomes for advanced melanoma. It uses a blood test (ctDNA) to decide who gets the extra drug.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older.
- You have advanced melanoma (stage IIIB-IV) that cannot be removed by surgery.
- You have not had prior cancer treatment for advanced or metastatic melanoma.
- You are planning to start the standard first-line therapy (nivolumab/relatlimab).
- You have a blood test showing ctDNA (a piece of tumor DNA in your blood).
- You have good organ function and are in reasonably good health (ECOG 0 or 1).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a combination of two immunotherapy drugs, nivolumab and relatlimab, for people with melanoma that cannot be removed by surgery or has spread. The treatment aims to help the immune system fight the cancer more effectively.
This trial tests a new drug (iSCIB1+) combined with two standard immunotherapy drugs (ipilimumab and nivolumab) as the first treatment for advanced melanoma that cannot be removed by surgery. The goal is to see if adding iSCIB1+ helps the immune system fight the cancer better.
This trial tests a new immunotherapy drug (IMC-F106C) combined with standard treatments against the usual nivolumab-based therapy for people with advanced melanoma who have not been treated before. It's for people who carry a specific immune system marker (HLA-A*02:01) and are in fairly good health.
This trial tests a combination of three immunotherapy drugs (fianlimab, cemiplimab, and ipilimumab) for people with advanced melanoma that has stopped responding to previous PD-1/PD-L1 treatment. It aims to see if this new combination can help shrink or control the cancer.
This trial tests a new combination of two immunotherapy drugs plus a targeted therapy (bevacizumab) for people with advanced melanoma whose cancer continued to grow after previous immunotherapy. The goal is to see if this combination can help control the cancer.
This trial tests a combination of an investigational viral therapy (VO) and the immunotherapy nivolumab for people with advanced melanoma that has stopped responding to previous anti-PD-1 and anti-CTLA-4 treatments. The goal is to see if this combination works better than other standard treatments your doctor might choose.
Hear when a new Metastatic Melanoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.